KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Cost of Revenue (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Cost of Revenue for 13 consecutive years, with $23.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Cost of Revenue fell 11.84% to $23.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $74.6 million, a 4.29% decrease, with the full-year FY2025 number at $74.6 million, down 4.29% from a year prior.
  • Cost of Revenue was $23.0 million for Q4 2025 at Supernus Pharmaceuticals, up from $19.0 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $26.1 million in Q4 2024 to a low of $15.0 million in Q1 2021.
  • A 5-year average of $19.9 million and a median of $19.3 million in 2023 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: surged 260.16% in 2021, then crashed 30.48% in 2024.
  • Supernus Pharmaceuticals' Cost of Revenue stood at $17.0 million in 2021, then surged by 35.07% to $23.0 million in 2022, then decreased by 14.49% to $19.6 million in 2023, then surged by 32.97% to $26.1 million in 2024, then dropped by 11.84% to $23.0 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Cost of Revenue are $23.0 million (Q4 2025), $19.0 million (Q3 2025), and $16.8 million (Q2 2025).